Valuation: Ind-Swift Laboratories Limited

Market Cap 11.4B 120M 104M 97.22M 88.93M 168M 170M 1.14B 446M 5.69B 449M 439M 18.95B P/E 2024
1.41x
P/E 2025 2.38x
Enterprise Value 7.13B 74.86M 64.96M 60.83M 55.64M 105M 106M 712M 279M 3.56B 281M 275M 11.86B EV / Sales 2024
0.14x
EV / Sales 2025 0.12x
Free-Float
40.72%
Yield 2024 *
-
Yield 2025 -
1 day-1.99%
1 week+0.91%
Current month+0.65%
1 month+5.70%
3 months+58.05%
6 months+84.84%
Current year+156.55%
1 week 215.5
Extreme 215.5
237.45
1 month 213.15
Extreme 213.15
248
Current year 88.5
Extreme 88.5
248
1 year 87
Extreme 87
248
3 years 67.15
Extreme 67.15
248
5 years 51.1
Extreme 51.1
248
10 years 15.25
Extreme 15.25
248
Manager TitleAgeSince
Chief Executive Officer 74 04/01/1995
Chief Executive Officer 44 15/06/2011
Director of Finance/CFO - 29/09/2018
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 23/03/2010
Change 5-day change 1-year change 3-year change Capi.($)
-1.99%+0.91% - - 211M
+0.57%-1.95%+19.54%+71.30% 48.95B
+3.09%+5.78%+64.08%+134.31% 39.36B
+1.25%+0.18%-1.52%+22.09% 12.39B
-1.17%-1.31%+15.39%+70.53% 11.76B
+1.53%-0.38%+30.75%+134.53% 9.14B
-0.25%+2.90%+18.08%+33.63% 7.05B
+1.61%-6.16%+38.63%-12.74% 6.86B
+0.49%+0.37%+10.59%+182.50% 6.7B
-1.46%+2.33%-30.59%+14.13% 5.67B
Average +0.37%-0.47%+18.33%+72.25% 16.43B
Weighted average by Cap. +1.14%-0.40%+28.48%+84.95%

Financials

2024 2025
Net sales 12.97B 136M 118M 111M 101M 191M 194M 1.29B 508M 6.48B 511M 500M 21.57B 5.62B 58.97M 51.17M 47.92M 43.83M 82.75M 83.83M 561M 220M 2.81B 221M 217M 9.34B
Net income 4.21B 44.19M 38.35M 35.91M 32.85M 62.01M 62.82M 420M 165M 2.1B 166M 162M 7B 2.5B 26.29M 22.82M 21.37M 19.55M 36.9M 37.38M 250M 98.1M 1.25B 98.72M 96.58M 4.17B
Net Debt -4.15B -43.6M -37.83M -35.43M -32.41M -61.18M -61.98M -414M -163M -2.08B -164M -160M -6.91B -4.27B -44.78M -38.86M -36.39M -33.28M -62.84M -63.66M -426M -167M -2.13B -168M -164M -7.09B
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,246
Date Price Change Volume
06/08/26 226.25 -1.99% 30,635
05/08/26 ₹230.85 +0.13% 18,980
04/08/26 ₹230.55 +1.16% 16,024
03/08/26 ₹227.90 +1.38% 13,020
31/07/26 ₹224.80 +2.37% 30,540